Details of the Drug

General Information of Drug (ID: DMYXDB9)

• Drug Name: NN-8828
• Synonyms: NNC-114-0005; NNC-0114-0000-0005; Anti-IL-21 (inflammation), Novo Nordisk; MIL-21 monoclonal antibody (autoimmune/chronic inflammatory disease), ZymoGenetics; Anti-IL-21 mAb (autoimmune/chronic inflammatory disease), Novo Nordisk; Anti-IL-21 mAb (autoimmune/chronic inflammatory disease), ZymoGenetics; Anti-IL-21 monoclonal antibody (autoimmune/chronic inflammatory disease), ZymoGenetics

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Phase 1	[1]

• Drug Type: Antibody
• Cross-matching ID: TTD ID: D05ZSX

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-21 (IL21)	TT9QEJ6	IL21_HUMAN	Not Available	[2]

Molecular Expression Atlas of This Drug

• The Studied Disease: Autoimmune diabetes
• ICD Disease Classification: 5A10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin-21 (IL21)	DTT	IL21	2.92E-02	0.09	1.42

References

• [1] ClinicalTrials.gov (NCT01208506) First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
• [2] Handbook of Therapeutic Antibodies. 2014. 1. Page(995).